metaPreg - Primidone (All indications) during pregnancy

Primidone (All indications) updated on 04-22-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	2.62 [1.37, 5.01]	0%	10 studies	49,686	165	low	ROB	4.69 [2.09; .]
Major congenital malformations	2.32 [1.04, 5.19]	9%	8 studies	49,669	126	not evaluable	ROB	4.07 [1.23; .]
Minor congenital malformations	3.46 [0.38, 31.70]	0%	2 studies	12	33	not evaluable	ROB	-
Neural Tube Defects	1.01 [0.06, 17.08]	0%	2 studies	1	41	not evaluable	ROB	-
8 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	6.23 [0.60, 64.99]	70%	2 studies	391	34	not evaluable	ROB	-
Small for gestational age (weight)	4.73 [0.22, 101.21]	50%	2 studies	446,275	35	not evaluable	ROB	-
1 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
3 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neuro-developmental disorders (as a whole)	2.15 [0.15, 30.90]	0%	2 studies	4	4	not evaluable	ROB	-
3 non statistically significant endpoints reported in only one study